Teva Pharmaceuticals USA and related affiliates of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and the state of Oklahoma, have entered into an agreement for a one-time payment of $85 million to the state.
Jazz Pharmaceuticals, Lundbeck and Alexion Pharmaceuticals have agreed to pay a total of $122.6m to resolve allegations of paying kickbacks through copay assistance foundations.
Bayer has entered into a $775m settlement agreement with Janssen Pharmaceuticals to resolve litigation related with blood thinner medication Xarelto.
The US Federal Trade Commission (FTC) and Israel-based Teva Pharmaceuticals Industries have reached a global settlement to resolve three separate federal court antitrust lawsuits involving the latter’s subsidiaries.
The US court has cleared way for Dr. Reddy's Laboratories to launch generic version of Indivior’s Suboxone (buprenorphine and naloxone) sublingual film, which is an opioid addiction treatment.
Clinical-stage biopharmaceutical firm Pain Therapeutics has petitioned the Food and Drug Administration (FDA) regarding a complete response Letter (CRL) for Remoxy issued in August this year.
Silence Therapeutics has received a notice of intention to grant for a new European divisional patent, EP 3 222 724B, and started a new cross-border interim injunction application in the Netherlands against Alnylam's Onpattro (patisiran).
AIDS Healthcare Foundation (AHF) has filed a petition for writ of certiorari (a petition for review) with the Supreme Court of the US, seeking the Court’s review of the dismissal of a federal lawsuit filed by AHF in January 2016 against Gilead Sciences and other defendants alleging its patent for a key HIV/AIDS drug, tenofovir alafenamide (TAF) is invalid because Gilead manipulated the patent system.
AstraZeneca has agreed to pay $110m to settle Texas drugs lawsuit claims of fraudulently marketing Seroquel and Crestor.
A US court has approved Indivior’s preliminary injunction (PI) preventing Dr. Reddy's Laboratories (DRL) from marketing of generic opioid addiction treatment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.